Literature DB >> 31391268

TMPRSS2 Is the Major Activating Protease of Influenza A Virus in Primary Human Airway Cells and Influenza B Virus in Human Type II Pneumocytes.

Hannah Limburg1, Anne Harbig1, Dorothea Bestle1, David A Stein2, Hong M Moulton2, Julia Jaeger1, Harshavardhan Janga3, Kornelia Hardes1, Janine Koepke3,4, Leon Schulte3, Andreas Rembert Koczulla4, Bernd Schmeck3,5, Hans-Dieter Klenk1, Eva Böttcher-Friebertshäuser6.   

Abstract

Cleavage of influenza virus hemagglutinin (HA) by host cell proteases is essential for virus infectivity and spread. We previously demonstrated in vitro that the transmembrane protease TMPRSS2 cleaves influenza A virus (IAV) and influenza B virus (IBV) HA possessing a monobasic cleavage site. Subsequent studies revealed that TMPRSS2 is crucial for the activation and pathogenesis of H1N1pdm and H7N9 IAV in mice. In contrast, activation of H3N2 IAV and IBV was found to be independent of TMPRSS2 expression and supported by an as-yet-undetermined protease(s). Here, we investigated the role of TMPRSS2 in proteolytic activation of IAV and IBV in three human airway cell culture systems: primary human bronchial epithelial cells (HBEC), primary type II alveolar epithelial cells (AECII), and Calu-3 cells. Knockdown of TMPRSS2 expression was performed using a previously described antisense peptide-conjugated phosphorodiamidate morpholino oligomer, T-ex5, that interferes with splicing of TMPRSS2 pre-mRNA, resulting in the expression of enzymatically inactive TMPRSS2. T-ex5 treatment produced efficient knockdown of active TMPRSS2 in all three airway cell culture models and prevented proteolytic activation and multiplication of H7N9 IAV in Calu-3 cells and H1N1pdm, H7N9, and H3N2 IAV in HBEC and AECII. T-ex5 treatment also inhibited the activation and spread of IBV in AECII but did not affect IBV activation in HBEC and Calu-3 cells. This study identifies TMPRSS2 as the major HA-activating protease of IAV in human airway cells and IBV in type II pneumocytes and as a potential target for the development of novel drugs to treat influenza infections.IMPORTANCE Influenza A viruses (IAV) and influenza B viruses (IBV) cause significant morbidity and mortality during seasonal outbreaks. Cleavage of the viral surface glycoprotein hemagglutinin (HA) by host proteases is a prerequisite for membrane fusion and essential for virus infectivity. Inhibition of relevant proteases provides a promising therapeutic approach that may avoid the development of drug resistance. HA of most influenza viruses is cleaved at a monobasic cleavage site, and a number of proteases have been shown to cleave HA in vitro This study demonstrates that the transmembrane protease TMPRSS2 is the major HA-activating protease of IAV in primary human bronchial cells and of both IAV and IBV in primary human type II pneumocytes. It further reveals that human and murine airway cells can differ in their HA-cleaving protease repertoires. Our data will help drive the development of potent and selective protease inhibitors as novel drugs for influenza treatment.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  TMPRSS2; hemagglutinin cleavage; host cell proteases; influenza virus; murine airway cells; primary human airway cells; protease inhibitors

Mesh:

Substances:

Year:  2019        PMID: 31391268      PMCID: PMC6803253          DOI: 10.1128/JVI.00649-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation.

Authors:  J Chen; K H Lee; D A Steinhauer; D J Stevens; J J Skehel; D C Wiley
Journal:  Cell       Date:  1998-10-30       Impact factor: 41.582

2.  A DNA transfection system for generation of influenza A virus from eight plasmids.

Authors:  E Hoffmann; G Neumann; Y Kawaoka; G Hobom; R G Webster
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

3.  Inhibition of multiple subtypes of influenza A virus in cell cultures with morpholino oligomers.

Authors:  Qing Ge; Manoj Pastey; Darwyn Kobasa; Piliapan Puthavathana; Christopher Lupfer; Richard K Bestwick; Patrick L Iversen; Jianzhu Chen; David A Stein
Journal:  Antimicrob Agents Chemother       Date:  2006-09-11       Impact factor: 5.191

4.  TMPRSS2 is a host factor that is essential for pneumotropism and pathogenicity of H7N9 influenza A virus in mice.

Authors:  Carolin Tarnow; Géraldine Engels; Annika Arendt; Folker Schwalm; Hanna Sediri; Annette Preuss; Peter S Nelson; Wolfgang Garten; Hans-Dieter Klenk; Gülsah Gabriel; Eva Böttcher-Friebertshäuser
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

5.  Cleavage activation of human-adapted influenza virus subtypes by kallikrein-related peptidases 5 and 12.

Authors:  Brian S Hamilton; Gary R Whittaker
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

6.  Morpholino oligomers targeting the PB1 and NP genes enhance the survival of mice infected with highly pathogenic influenza A H7N7 virus.

Authors:  Gülsah Gabriel; Alexandra Nordmann; David A Stein; Patrick L Iversen; Hans-Dieter Klenk
Journal:  J Gen Virol       Date:  2008-04       Impact factor: 3.891

7.  Hemagglutinin activating host cell proteases provide promising drug targets for the treatment of influenza A and B virus infections.

Authors:  Eva Böttcher-Friebertshäuser; Yinghui Lu; Daniela Meyer; Frank Sielaff; Torsten Steinmetzer; Hans-Dieter Klenk; Wolfgang Garten
Journal:  Vaccine       Date:  2012-10-13       Impact factor: 3.641

8.  Endogenous protease-dependent replication of human influenza viruses in two MDCK cell lines.

Authors:  K Noma; K Kiyotani; H Kouchi; Y Fujii; Y Egi; K Tanaka; T Yoshida
Journal:  Arch Virol       Date:  1998       Impact factor: 2.574

9.  Is virulence of H5N2 influenza viruses in chickens associated with loss of carbohydrate from the hemagglutinin?

Authors:  Y Kawaoka; C W Naeve; R G Webster
Journal:  Virology       Date:  1984-12       Impact factor: 3.616

10.  Non-human primate orthologues of TMPRSS2 cleave and activate the influenza virus hemagglutinin.

Authors:  Pawel Zmora; Paulina Molau-Blazejewska; Stephanie Bertram; Kerstin Walendy-Gnirß; Inga Nehlmeier; Anika Hartleib; Anna-Sophie Moldenhauer; Sebastian Konzok; Susann Dehmel; Katherina Sewald; Constantin Brinkmann; Christoph Curths; Sascha Knauf; Jens Gruber; Kerstin Mätz-Rensing; Franziska Dahlmann; Armin Braun; Stefan Pöhlmann
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

View more
  46 in total

1.  Hemagglutinin Cleavability, Acid Stability, and Temperature Dependence Optimize Influenza B Virus for Replication in Human Airways.

Authors:  Manon Laporte; Annelies Stevaert; Valerie Raeymaekers; Talitha Boogaerts; Inga Nehlmeier; Winston Chiu; Mohammed Benkheil; Bart Vanaudenaerde; Stefan Pöhlmann; Lieve Naesens
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

2.  Transcriptome profiling and protease inhibition experiments identify proteases that activate H3N2 influenza A and influenza B viruses in murine airways.

Authors:  Anne Harbig; Marco Mernberger; Linda Bittel; Stephan Pleschka; Klaus Schughart; Torsten Steinmetzer; Thorsten Stiewe; Andrea Nist; Eva Böttcher-Friebertshäuser
Journal:  J Biol Chem       Date:  2020-04-17       Impact factor: 5.157

3.  Epipharyngeal Abrasive Therapy Down-regulates the Expression of Cav1.2: A Key Molecule in Influenza Virus Entry.

Authors:  Kensuke Nishi; Shohei Yoshimoto; Soichiro Nishi; Tatsuro Nishi; Ryushiro Nishi; Toshiyuki Tsunoda; Hiromitsu Morita; Hiroaki Tanaka; Osamu Hotta; Susumu Yasumasu; Kenji Hiromatsu; Senji Shirasawa; Takashi Nakagawa; Takafumi Yamano
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

4.  Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation.

Authors:  Bryan J Fraser; Serap Beldar; Almagul Seitova; Ashley Hutchinson; Dhiraj Mannar; Yanjun Li; Daniel Kwon; Ruiyan Tan; Ryan P Wilson; Karoline Leopold; Sriram Subramaniam; Levon Halabelian; Cheryl H Arrowsmith; François Bénard
Journal:  Nat Chem Biol       Date:  2022-06-08       Impact factor: 16.174

5.  Prevalence of telogen effluvium hair loss in COVID-19 patients and its relationship with disease severity.

Authors:  Shahram Seyfi; Robabeh Alijanpour; Zeinab Aryanian; Khadijeh Ezoji; Mahdi Mahmoudi
Journal:  J Med Life       Date:  2022-05

6.  Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture.

Authors:  Lukas Wettstein; Philip Maximilian Knaff; Christian Kersten; Patrick Müller; Tatjana Weil; Carina Conzelmann; Janis A Müller; Maximilian Brückner; Markus Hoffmann; Stefan Pöhlmann; Tanja Schirmeister; Katharina Landfester; Jan Münch; Volker Mailänder
Journal:  Commun Biol       Date:  2022-07-08

7.  Development of Lentiviral Vectors Pseudotyped With Influenza B Hemagglutinins: Application in Vaccine Immunogenicity, mAb Potency, and Sero-Surveillance Studies.

Authors:  Francesca Ferrara; Joanne Marie M Del Rosario; Kelly A S da Costa; Rebecca Kinsley; Simon Scott; Sasan Fereidouni; Craig Thompson; Paul Kellam; Sarah Gilbert; George Carnell; Nigel Temperton
Journal:  Front Immunol       Date:  2021-05-24       Impact factor: 7.561

Review 8.  The probable destructive mechanisms behind COVID-19 on male reproduction system and fertility.

Authors:  Mojgan Moshrefi; Saeed Ghasemi-Esmailabad; Jaffar Ali; Necati Findikli; Esmat Mangoli; Mohammad Ali Khalili
Journal:  J Assist Reprod Genet       Date:  2021-05-11       Impact factor: 3.412

Review 9.  Insights into disparities observed with COVID-19.

Authors:  J M Carethers
Journal:  J Intern Med       Date:  2020-12-06       Impact factor: 13.068

10.  Hemagglutinins of Avian Influenza Viruses Are Proteolytically Activated by TMPRSS2 in Human and Murine Airway Cells.

Authors:  Dorothea Bestle; Hannah Limburg; Diana Kruhl; Anne Harbig; David A Stein; Hong Moulton; Mikhail Matrosovich; Elsayed M Abdelwhab; Jürgen Stech; Eva Böttcher-Friebertshäuser
Journal:  J Virol       Date:  2021-07-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.